According to a recent article from Scrip, Dr. Reddy’s Laboratories has secured regional rights to a pair of biosimilars from Bio-Thera, a Chinese biotech company. The agreement grants Dr. Reddy’s the rights to commercialize Bio-Thera’s pegfedimondas ( pegfedlatin) and joblatu (adalimumab-rogen) biosimilars in various Asian markets, including India, China, and Southeast Asia.
Pegfedimondas, also known as FB-027, is a pegylated pegfilgrastim biosimilar, which is used to treat neutropenia, a condition characterized by low white blood cell count. Joblatu, or BT-081, is a biosimilar of Humira (adalimumab), a biologic medicine used to treat various autoimmune disorders.
The agreement marks a significant expansion for both Dr. Reddy’s and Bio-Thera, as they diversify their portfolios and reach new geographies. Dr. Reddy’s, an Indian pharma major, has been actively pursuing in-licensing agreements to strengthen its biosimilars pipeline, while Bio-Thera continues to grow its global presence through strategic partnerships.
This deal demonstrates the growing trend of partnerships between Indian and Chinese pharmaceutical companies, as they seek to leverage each other’s expertise, resources, and local knowledge to fuel growth. The agreement also underscores the increasing importance of biosimilars in Asia, where demand for affordable, high-quality biologics is growing rapidly.
The terms of the agreement have not been disclosed, but it is likely that Dr. Reddy’s will benefit from Bio-Thera’s expertise in developing and commercializing biosimilars, while Bio-Thera will gain access to Dr. Reddy’s established distribution network and local knowledge in the Asian market.
The agreement is also significant in the context of India’s growing biosimilars industry, with the country’s pharma sector poised to benefit from the increasing demand for affordable biologics. As Dr. Reddy’s looks to strengthen its biosimilars pipeline, this deal represents a key milestone in its efforts to become a major player in the global biosimilars market.
Overall, the agreement between Dr. Reddy’s and Bio-Thera highlights the growing trend of collaborations between Indian and Chinese pharma companies, as they seek to capitalize on each other’s strengths and expertise to fuel growth and tap into the rapidly expanding Asian biosimilars market.